CORDIS
EU research results

CORDIS

English EN

Novel nanotechnology-enabled system for endovascular in vivo near-infrared fluorescence molecular imaging and endovascular near-infrared targeted photodynamic therapy of atherosclerotic heart disease

Objective

CosmoPHOS-nano is a multidisciplinary, translational and business-oriented project, aiming to accomplish the following objectives:
1) develop the CosmoPHOS system, which is a novel theranostic (diagnostic & therapeutic) nanotechnology-enabled portable combination system enabling endovascular in vivo near-infrared fluorescence molecular imaging, endovascular near-infrared targeted photodynamic therapy, real-time & follow-up therapy monitoring of atherosclerotic coronary artery disease (CAD),
2) nonclinically evaluate this system,
3) clinically validate the system after regulatory approval, &
4) reduce in the long-term CAD deaths and morbidity by up to 40%, resulting in a significant decrease of the European and global healthcare costs for CAD, increasing the income of the European healthcare industry from CAD market which is the global largest. The CosmoPHOS-nano consortium has a five year history of successful collaboration between the industrial and academic partners, and its funding would underpin a team devoted to delivering a novel powerful & affordable healthcare solution against the leading cause of death, without the need for heavy and expensive medical equipment.
The CosmoPHOS system consists of two interacting components:
a) targeted theranostic near-infrared photoactivatable biocompatible nanomedicines, and
b) medical devices.
After systemic administration, the nanomedicines targeted accumulate in coronary atherosclerotic plaques, followed by endocoronary photoactivation and detection by the medical devices, enabling molecular imaging, targeted therapy, real-time & follow-up therapy monitoring of CAD. Preliminary in vitro & in vivo successful experimental results, as well as parts of the CosmoPHOS system are already available from the prior five year collaboration.
The project plan includes: A) nonclinical R&D (30 months); B) nonclinical validation & regulatory approval (18 months); C) first-in-man phase-I clinical trial in 20 CAD patients (12 months).
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ITA-SUOMEN YLIOPISTO

Address

Yliopistonranta 1 E
70211 Kuopio

Finland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 029 689,65

Administrative Contact

Jaana Backman (Ms.)

Participants (18)

Sort alphabetically

Sort by EU Contribution

Expand all

COSMOPHOS LTD

Greece

EU Contribution

€ 499 540

FREIE UNIVERSITAET BERLIN

Germany

EU Contribution

€ 523 735

UNIVERSIDAD AUTONOMA DE MADRID

Spain

EU Contribution

€ 679 426

TECHNISCHE UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 657 547

Fujikura Europe Ltd

United Kingdom

EU Contribution

€ 75 060

KOBENHAVNS UNIVERSITET

Denmark

EU Contribution

€ 844 768

FIBERTECH CO., LTD

Japan

SEMMELWEIS EGYETEM

Hungary

EU Contribution

€ 210 652

TOXI-COOP TOXIKOLOGIAI KUTATO KOZPONT ZARTKORUEN MUKODO RT

Hungary

EU Contribution

€ 500 275

UNIVERSITEIT UTRECHT

Netherlands

EU Contribution

€ 284 337,75

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 310 088

BIOCONTRACT SP ZOO

Poland

EU Contribution

€ 303 032

IFOM FONDAZIONE ISTITUTO FIRC DI ONCOLOGIA MOLECOLARE

Italy

EU Contribution

€ 312 592,40

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 328 120

LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE

United States

ETHNIKO IDRYMA EREVNON

Greece

EU Contribution

€ 223 194

EURAM LIMITED

United Kingdom

EU Contribution

€ 374 400

POHJOIS-SAVON SAIRAANHOITOPIIRIN KUNTAYHTYMA

Finland

EU Contribution

€ 346 895,20

Project information

Grant agreement ID: 310337

Status

Closed project

  • Start date

    1 March 2013

  • End date

    28 February 2018

Funded under:

FP7-NMP

  • Overall budget:

    € 12 899 591,80

  • EU contribution

    € 8 503 352

Coordinated by:

ITA-SUOMEN YLIOPISTO

Finland